Recent Updates
Recently added Catalysts
SABS Positive Sentiment

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

Tuesday, July 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Breakthrough T1D has awarded a grant to SAB Biotherapeutics to support the PRISE-hATG study. This study focuses on the use of SAB-142, a fully human anti-thymocyte immunoglobulin, for patients with Stage 3 Type 1 Diabetes. The funding aims to enhance research and development in this critical area of diabetes treatment.
Price reaction · baseline $3.92 (2026-07-06 close) · hit pre-market · clean, no other SABS news in the window
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Breakthrough T1D awarded a grant to support the PRISE-hATG study.
  • SAB Biotherapeutics is advancing its clinical-stage therapy for Type 1 Diabetes.
  • The study aims to improve treatment options for patients with Stage 3 T1D.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
25.7%
average across 4 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
SAB-142
Phase 3 · Type 1 Diabetes (T1D)

Full Press Release Details

MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and

Frequently Asked Questions

What is the purpose of the PRISE-hATG study?

The PRISE-hATG study aims to evaluate the efficacy of SAB-142 in treating Stage 3 Type 1 Diabetes.

Who awarded the grant for the SAB-142 study?

The grant was awarded by Breakthrough T1D, a leading organization in type 1 diabetes research.

What is SAB-142?

SAB-142 is a fully human anti-thymocyte immunoglobulin developed by SAB Biotherapeutics for T1D.

What stage of diabetes is the study focused on?

The study focuses on patients with Stage 3 Type 1 Diabetes.

ShareAdd on Google
Tags: SABS Viatris Investor Conferences Healthcare SAB Biotherapeutics Type 1 Diabetes PRISE-hATG SAB-142 clinical-stage therapy
Last updated: Jul 7, 2026

Biotech snapshot

Cash runway
$103M liquidity · $3M/mo burn
~31 mo
Minimal dilution risk
Lead asset
SAB-142Phase 3
Type 1 Diabetes (T1D) →

Catalyst track record

+19%
best trade around SABS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SABS.

See every catalyst's timing & PoA →